Targovax ASA: Two abstracts accepted at the SITC Congress
Oslo, Norway, 6 October 2021 - Targovax ASA (OSE: TRVX), a clinical stage immuno-oncology company developing immune activators to target hard-to-treat solid tumors, today announces that two abstracts has been accepted for poster presentation at the Society for Immunotherapy of Cancer (SITC) Annual Meeting.The abstracts will be released on the SITC website 9 November 14:00 CEST (www.sitcancer.org/2021/home). The posters are scheduled for presentation during the SITC congress 12-14 November 2021. Poster A randomised open-label phase I/II study adding ONCOS-102 totitle: pemetrexed/